Iruplinalkib
PreclinicalSmall molecule
Qilu Pharmaceutical Co., Ltd.Iruplinalkib is one of 78 small molecule programs targeting Lung Adenocarcinoma. It is currently in Preclinical.
2
Indications
6
Total Trials
5
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Treatment
GSKPreclinical
REGN2810
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer2 trials
Neoadjuvant Therapy1 trial
Iruplinalkib1 trial
Lung Adenocarcinoma1 trial
Postoperative Adjuvant Therapy1 trial
Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07330076·28 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iruplinalkib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details